62 research outputs found
Construção e validação de uma escala de resiliência comunitária ameaças naturais
Background: The effects caused by natural phenomena have been increasing, aggravating the vulnerability of exposed populations. It is necessary to measure the resilience capacity of the community to face this type of adverse situations. The objective of the study was the construction and validation of a self-report scale of community resilience. Method: The items were based on the proposal of Twigg (2007) and Suárez-Ojeda (2001). The AIKEN V and semi-confirmatory analysis (McDonald, 2005) were used to validate the instrument. There was a sample of 290 participants with an age range of 18 to 78 years, from the municipalities of Jojutla and Yautepec in the State of Morelos (Mexico). Results: A final unidimensional scale made up of 16 items was obtained, internal consistency Ω = .924. Conclusions: This scale can be useful for those working in integrated disaster risk management.Antecedentes: Los efectos ocasionados por los fenómenos de origen natural han ido en aumento, agravando la vulnerabilidad de las poblaciones expuestas. Resulta necesario medir la capacidad de resiliencia de la comunidad para hacer frente a este tipo de situaciones adversas. El objetivo del estudio fue la construcción y validación de una escala de autoinforme de resiliencia comunitaria. Método: Los ítems se basaron en la propuesta de Twigg (2007) y Suárez-Ojeda (2001). Para la validación del instrumento se empleó la V de Aiken y el análisis semi-confirmatorio (McDonald, 2005). Se contó con una muestra de 290 participantes con un rango de edad de 18 a 78 años, de los municipios de Jojutla y Yautepec del Estado de Morelos (México). Resultados: Se obtuvo una escala final unidimensional conformada por 16 ítems, consistencia interna Ω = .924. Conclusiones: Esta escala puede ser de utilidad para quienes trabajan en la gestión integral de riesgos de desastres.Antecedentes: Os efeitos causados por fenômenos naturais vêm aumentando, agravando a vulnerabilidade das populações expostas. É necessário mensurar a capacidade de resiliência da comunidade para lidar com esse tipo de situação adversa. O objetivo do estudo foi a construção e a validação de uma escala de autorrelato de resiliência comunitária. Método: Os itens foram baseados na proposta de Twigg (2007) e Suárez-Ojeda (2001). Para validação do instrumento, utilizou-se o V do AIKEN e a análise semiconfirmatória (McDonald, 2005). A amostra foi de 290 participantes, com faixa etária de 18 a 78 anos, dos municípios de Jojutla e Yautepec do Estado de Morelos (México). Resultados: Obteve-se uma escala final unidimensional composta por 16 itens, consistência interna Ω = 0,924. Conclusões: Esta escala pode ser útil para quem trabalha na gestão integral do risco de desastres
Perinatal exposure to pesticides alters synaptic plasticity signaling and induces behavioral deficits associated with neurodevelopmental disorders.
Increasing evidence from animal and epidemiological studies indicates that perinatal exposure to pesticides cause developmental neurotoxicity and may increase the risk for psychiatric disorders such as autism and intellectual disability. However, the underlying pathogenic mechanisms remain largely elusive. This work was aimed at testing the hypothesis that developmental exposure to different classes of pesticides hijacks intracellular neuronal signaling contributing to synaptic and behavioral alterations associated with neurodevelopmental disorders (NDD). Low concentrations of organochlorine (dieldrin, endosulfan, and chlordane) and organophosphate (chlorpyrifos and its oxon metabolite) pesticides were chronically dosed ex vivo (organotypic rat hippocampal slices) or in vivo (perinatal exposure in rats), and then biochemical, electrophysiological, behavioral, and proteomic studies were performed. All the pesticides tested caused prolonged activation of MAPK/ERK pathway in a concentration-dependent manner. Additionally, some of them impaired metabotropic glutamate receptor-dependent long-term depression (mGluR-LTD). In the case of the pesticide chlordane, the effect was attributed to chronic modulation of MAPK/ERK signaling. These synaptic alterations were reproduced following developmental in vivo exposure to chlordane and chlorpyrifos-oxon, and were also associated with prototypical behavioral phenotypes of NDD, including impaired motor development, increased anxiety, and social and memory deficits. Lastly, proteomic analysis revealed that these pesticides differentially regulate the expression of proteins in the hippocampus with pivotal roles in brain development and synaptic signaling, some of which are associated with NDD. Based on these results, we propose a novel mechanism of synaptic dysfunction, involving chronic overactivation of MAPK and impaired mGluR-LTD, shared by different pesticides which may have important implications for NDD.Open Access funding provided thanks to the
CRUE-CSIC agreement with Springer Nature. This work was
supported by the Intertalentum Postdoctoral Program (Marie
Curie cofund UAM-UE, EU project 713366) for V.B. and by
grants from the Spanish Ministry of Science and Innovation
(SAF2017-86983-R, PID2020-117651RB) and from the Spanish Ministry of Economy and Competitiveness (PCIN-2016–
095) for J.A.E.. V.B. was also recipient of the 2019 Eduardo
Gallego postdoctoral fellowship from Fundación Francisco
Cobos. M.I.C. was recipient of a postdoctoral fellowship from
the Spanish Ministry of Economy (IJCI-2015–25507). E.LM.
was recipient of a predoctoral fellowship from the Spanish
Ministry of Science and Innovation (FPU18/02838).S
From olive leaves to spherical nanoparticles by one-step RESS process precipitation
In this work, spherical nanoparticles to be used in cosmetic, agro food or pharmaceutical industries have been directly precipitated from olives leaves in one-step RESS process. The leaves were brought into contact with supercritical CO2, and a fraction of the compounds from the flavone and flavonol families that can be found in the leaves were dissolved; then, by depressurizing the vessel, these compounds formed particles in the nanometer range. A complete factorial design was generated to thoroughly determine the influence from the main parameters on the RESS process with respect to the precipitated nanoparticles and their heterogeneity. Their antioxidant activity was also evaluated. Different pressures (250-350 bar), temperatures (60 and 100 degrees C), leaves sample weights (2 and 4 g) and cosolvent volumes, namely ethanol (9 and 18 mL), were studied as the main parameters that could affect the solvation and precipitation of the particle with active compounds in the leaves. Other parameters such as contact time (1 h) or nozzle size diameter (100 mu m) remained unchanged. The antioxidant activity was evaluated by means of the radical scavenging method using the radical 2,2-diphenyl-1-picrylhydrazole (DPPH). Spherical particles with diameters in the range of 55 nm to 4 mu m were obtained. Lower pressures and higher temperatures seemed to result in a reduction of the mean particle size. Greater volume of cosolvent is also recommended to reduce mean particle size. However, lower pressure, temperature and volume of cosolvent seems to promote a greater homogeneity of the particles. By means of chromatographic analyses, the main compounds, responsible for the antioxidant activity, such as oleuropein, quercetin or apigenin among others were identified
Molecular Determinants of Kv1.3 Potassium Channels-induced Proliferation
Producción CientíficaChanges in voltage-dependent potassium channels (Kv channels) associate to proliferation in many cell types, including transfected HEK293 cells. In this system Kv1.5 overexpression decreases proliferation, whereas Kv1.3 expression increases it independently of K+ fluxes. To identify Kv1.3 domains involved in a proliferation-associated signaling mechanism(s), we constructed chimeric Kv1.3-Kv1.5 channels and point-mutant Kv1.3 channels, which were expressed as GFP- or cherry-fusion proteins. We studied their trafficking and functional expression, combining immunocytochemical and electrophysiological methods, and their impact on cell proliferation. We found that the C terminus is necessary for Kv1.3-induced proliferation. We distinguished two residues (Tyr-447 and Ser-459) whose mutation to alanine abolished proliferation. The insertion into Kv1.5 of a sequence comprising these two residues increased proliferation rate. Moreover, Kv1.3 voltage-dependent transitions from closed to open conformation induced MEK-ERK1/2-dependent Tyr-447 phosphorylation. We conclude that the mechanisms for Kv1.3-induced proliferation involve the accessibility of key docking sites at the C terminus. For one of these sites (Tyr-447) we demonstrated the contribution of MEK/ERK-dependent phosphorylation, which is regulated by voltage-induced conformational changes.Ministerio de Economía y Competitividad (MINECO), Instituto de Salud Carlos III y Programa Estatal de Investigación , Fundación Ramón Areces y Consejería de Sanidad de la Junta de Castilla y León
Talleres de propuestas y sugerencias de alumnos de Grado para la mejora del Programa Docentia
El Proyecto tiene como objetivo la implementacion de una Cultura de Calidad en los alumnos de grados de diferentes Grados de Ciencias de la Salud. Y el estudio de posibles vias y mecanismos para aumentar la implicacion de los alumnos de la UCM en el Programa Docentia
Real-world experience with bezlotoxumab for prevention of recurrence of Clostridioides difficile infection
Bezlotoxumab is marketed for the prevention of recurrent Clostridioides difficile infection
(rCDI). Its high cost could be determining its prescription to a different population than that represented
in clinical trials. The objective of the study was to verify the effectiveness and safety of
bezlotoxumab in preventing rCDI and to investigate factors related to bezlotoxumab failure in the
real world. A retrospective, multicentre cohort study of patients treated with bezlotoxumab in Spain
was conducted. We compared the characteristics of cohort patients with those of patients treated with
bezlotoxumab in the pivotal MODIFY trials. We assessed recurrence rates 12 weeks after completion
of treatment against C. difficile, and we analysed the factors associated with bezlotoxumab failure.
Ninety-one patients were included in the study. The cohort presented with more risk factors for rCDI
than the patients included in the MODIFY trials. Thirteen (14.2%) developed rCDI at 12 weeks of
follow-up, and rCDI rates were numerically higher in patients with two or more previous episodes (25%) than in those who had fewer than two previous episodes of C. difficile infection (CDI) (10.4%);
p = 0.09. There were no adverse effects attributable to bezlotoxumab. Despite being used in a more
compromised population than that represented in clinical trials, we confirm the effectiveness of bezlotoxumab for the prevention of rCDI
Oral fosfomycin for the treatment of lower urinary tract infections among kidney transplant recipients—Results of a Spanish multicenter cohort
Preliminary results of this study were presented at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), held in Amsterdam, The Netherlands, from 13 to 16 April, 2019 (oral communication O‐0699).Oral fosfomycin may constitute an alternative for the treatment of lower urinary tract infections (UTIs) in kidney transplant recipients (KTRs), particularly in view of recent safety concerns with fluroquinolones. Specific data on the efficacy and safety of fosfomycin in KTR are scarce. We performed a retrospective study in 14 Spanish hospitals including KTRs treated with oral fosfomycin (calcium and trometamol salts) for posttransplant cystitis between January 2005 and December 2017. A total of 133 KTRs developed 143 episodes of cystitis. Most episodes (131 [91.6%]) were produced by gram‐negative bacilli (GNB), and 78 (54.5%) were categorized as multidrug resistant (including extended‐spectrum β‐lactamase‐producing Enterobacteriaceae [14%] or carbapenem‐resistant GNB [3.5%]). A median daily dose of 1.5 g of fosfomycin (interquartile range [IQR]: 1.5‐2) was administered for a median of 7 days (IQR: 3‐10). Clinical cure (remission of UTI‐attributable symptoms at the end of therapy) was achieved in 83.9% (120/143) episodes. Among those episodes with follow‐up urine culture, microbiological cure at month 1 was achieved in 70.2% (59/84) episodes. Percutaneous nephrostomy was associated with a lower probability of clinical cure (adjusted odds ratio: 10.50; 95% confidence interval: 0.98‐112.29; P = 0.052). In conclusion, fosfomycin is an effective orally available alternative for treating cystitis among KTRs.This study was supported by Plan Nacional de I+D+i 2013‐2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Ciencia, Innovación y Universidades, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016)—cofinanced by the European Development Regional Fund “A way to achieve Europe”; the Group for Study of Infection in Transplantation and the Immunocompromised Host (GESITRA‐IC) of the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC); and the Spanish Network for Research in Renal Diseases (REDInREN RD16/0009). MFR holds a research contract “Miguel Servet” (CP 18/00073) from the Spanish Ministry of Science, Innovation and Universities, Instituto de Salud Carlos III
Safety and effectiveness of isavuconazole in real-life non-neutropenic patients
Objectives: Information is scarce on clinical experiences with non-neutropenic patients with invasive fungal infection (IFI) receiving isavuconazole. We aimed to report the safety and effectiveness of this drug as a first-line treatment or rescue in real life. Methods: A retrospective, observational multicentric study of non-neutropenic patients who received isavuconazole as an IFI treatment at 12 different university hospitals (January 2018-2022). All patients met criteria for proven, probable or possible IFI according to EORTC-MSG. Results: A total of 238 IFIs were treated with isavuconazole during the study period. Combination therapy was administered in 27.7% of cases. The primary IFI was aspergillosis (217, 91.2%). Other IFIs treated with isavuconazole were candidemia (n = 10), mucormycosis (n = 8), histoplasmosis (n = 2), cryptococcosis (n = 2), and others (n = 4). Median time of isavuconazole treatment was 29 days. Only 5.9% (n = 14) of cases developed toxicity, mainly hepatic-related (10 patients, 4.2%). Nine patients (3.8%) had treatment withdrawn. Successful clinical response at 12 weeks was documented in 50.5% of patients. Conclusion: Isavuconazole is an adequate treatment for non-neutropenic patients with IFIs. Toxicity rates were low and its effectiveness was comparable to other antifungal therapies previously reported. (c) 2024 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/
Revisiting the epidemiology of bloodstream infections and healthcare-associated episodes: results from a multicentre prospective cohort in Spain (PRO-BAC Study)
PROBAC REIPI/GEIH-SEIMC/SAEI Group.The epidemiology of bloodstream infections (BSIs) is dynamic as it depends on microbiological, host and healthcare system factors. The aim of this study was to update the information regarding the epidemiology of BSIs in Spain considering the type of acquisition. An observational, prospective cohort study in 26 Spanish hospitals from October 2016 through March 2017 including all episodes of BSI in adults was performed. Bivariate analyses stratified by type of acquisition were performed. Multivariate analyses were performed by logistic regression. Overall, 6345 BSI episodes were included; 2510 (39.8%) were community-acquired (CA), 1661 (26.3%) were healthcare-associated (HCA) and 2056 (32.6%) hospital-acquired (HA). The 30-day mortality rates were 11.6%, 19.5% and 22.0%, respectively. The median age of patients was 71 years (interquartile range 60–81 years) and 3656 (58.3%; 95% confidence interval 57.1–59.6%) occurred in males. The proportions according to patient sex varied according to age strata. Escherichia coli (43.8%), Klebsiella spp. (8.9%), Staphylococcus aureus (8.9%) and coagulase-negative staphylococci (7.4%) were the most frequent pathogens. Multivariate analyses confirmed important differences between CA and HCA episodes, but also between HCA and HA episodes, in demographics, underlying conditions and aetiology. In conclusion, we have updated the epidemiological information regarding patients’ profiles, underlying conditions, frequency of acquisition types and aetiological agents of BSI in Spain. HCA is confirmed as a distinct type of acquisition.This work was financed by grants from Plan Nacional de I+D+i 2013–2016, Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Ciencia, Innovación y Universidades [PI16/01432] and the Spanish Network for Research in Infectious Diseases (REIPI) [RD16/0016/0001; RD16/0016/0008], co‐financed by the European Development Regional Fund ‘A way to achieve Europe’, Operative program Intelligent Growth 2014–2020
Efficacy of β-lactam/β-lactamase inhibitors to treat extended-spectrum beta-lactamase-producing Enterobacterales bacteremia secondary to urinary tract infection in kidney transplant recipients (INCREMENT-SOT Project)
REIPI/INCREMENT-SOT Group.[Background] Whether active therapy with β-lactam/β-lactamase inhibitors (BLBLI) is as affective as carbapenems for extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E) bloodstream infection (BSI) secondary to urinary tract infection (UTI) in kidney transplant recipients (KTRs) remains unclear.[Methods] We retrospectively evaluated 306 KTR admitted to 30 centers from January 2014 to October 2016. Therapeutic failure (lack of cure or clinical improvement and/or death from any cause) at days 7 and 30 from ESBL-E BSI onset was the primary and secondary study outcomes, respectively.[Results] Therapeutic failure at days 7 and 30 occurred in 8.2% (25/306) and 13.4% (41/306) of patients. Hospital-acquired BSI (adjusted OR [aOR]: 4.10; 95% confidence interval [CI]: 1.50-11.20) and Pitt score (aOR: 1.47; 95% CI: 1.21-1.77) were independently associated with therapeutic failure at day 7. Age-adjusted Charlson Index (aOR: 1.25; 95% CI: 1.05-1.48), Pitt score (aOR: 1.72; 95% CI: 1.35-2.17), and lymphocyte count ≤500 cells/μL at presentation (aOR: 3.16; 95% CI: 1.42-7.06) predicted therapeutic failure at day 30. Carbapenem monotherapy (68.6%, primarily meropenem) was the most frequent active therapy, followed by BLBLI monotherapy (10.8%, mostly piperacillin-tazobactam). Propensity score (PS)-adjusted models revealed no significant impact of the choice of active therapy (carbapenem-containing vs any other regimen, BLBLI- vs carbapenem-based monotherapy) within the first 72 hours on any of the study outcomes.[Conclusions] Our data suggest that active therapy based on BLBLI may be as effective as carbapenem-containing regimens for ESBL-E BSI secondary to UTI in the specific population of KTR. Potential residual confounding and unpowered sample size cannot be excluded (ClinicalTrials.gov identifier: NCT02852902).This work was supported by: (1) Plan Nacional de I+D+i 2013-2016 and Instituto de Salud Carlos III (ISCIII), Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Ciencia, Innovación y Universidades, Spanish Network for Research in Infectious Diseases [RD16/0016/0001, RD16/0016/0002, REIPI RD16/0016/0008; RD16/0016/00010], co-financed by European Development Regional Fund “A way to achieve Europe”, Operative Program Intelligent Growth 2014-2020; (2) European Society of Clinical Microbiology and Infectious diseases Study Group for Infections in Compromised Hosts (ESGICH, grant to J.M.A.); (3) Sociedad Andaluza de Trasplante de Órgano Sólido (SATOT, grant to L.M.M.); (4) Research project PI16/01631 integrated into the Plan Estatal de I+D+I 2013-2016 and co-financed by the ISCIII-Subdirección General de Evaluación y Fomento de la Investigación and the Fondo Europeo de Desarrollo Regional (FEDER); (5) M.F.R. holds a research contract “Miguel Servet” (CP 18/00073) from ISCIII, Ministerio de Ciencia, Innovación y Universidades. The work was also supported by the following European Society of Clinical Microbiology and Infectious diseases (ESCMID) study groups: Infections in Compromised Hosts (ESGICH), Bloodstream Infections and Sepsis (ESGBIS) and Antimicrobial Resistance Surveillance (ESGARS).Peer reviewe
- …